National MS Society Urges DMT Dosing Changes for COVID-19 Vaccinations

National MS Society Urges DMT Dosing Changes for COVID-19 Vaccinations

286365

National MS Society Urges DMT Dosing Changes for COVID-19 Vaccinations

To potentially increase the effectiveness of COVID-19 vaccines in people with multiple sclerosis (MS), the National Multiple Sclerosis Society is recommending dosing adaptations for some disease-modifying therapies (DMTs). Based on expert consensus and available data, the guidance is particularly relevant for MS patients considering initiating or already being treated with such DMTs as Lemtrada (alemtuzumab), Mavenclad (cladribine), Ocrevus (ocrelizumab), off-label rituximab, or Kesimpta (ofatumumab). The two currently distributed COVID-19 vaccines in the U.S. — the…

You must be logged in to read/download the full post.